Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Inclusion Criteria: * Histologically confirmed endometrial carcinoma (from primary tumor) including any of the following cell types: * Endometrioid adenocarcinoma * Serous adenocarcinoma * Undifferentiated carcinoma * Clear cell adenocarcinoma * Mixed epithelial carcinoma * Adenocarcinoma not otherwise specified * Mucinous adenocarcinoma * Squamous cell carcinoma * Transitional cell carcinoma * Mesonephric carcinoma * Recurrent or persistent disease that is refractory to curative therapy or established treatments * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan * Must have ≥ 1 target lesion to assess response as defined by RECIST * Tumors within a previously irradiated field are designated as "non-target" lesions in the absence of documented disease progression or a biopsy to confirm persistence for ≥ 90 days after completion of radiotherapy * Must have received 1 prior chemotherapeutic regimen for management of endometrial carcinoma * May have received 1 additional cytotoxic regimen for management of this disease * Not eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, including any active GOG Phase III protocol for patients with endometrial carcinoma * No history or evidence of CNS disease, including primary brain tumor or any brain metastases upon physical examination * GOG performance status (PS) 0-2 (for patients who have received 1 prior regimen) OR PS 0-1 (for patients who have received 2 prior regimens) * ANC ≥ 1,500/mcL * Platelet count ≥ 100,000/mcL * Creatinine ≤ 1.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * SGOT ≤ 2.5 times ULN * Alkaline phosphatase ≤ 2.5 times ULN * Urine protein:creatinine ratio \< 1.0 OR urine protein \< 1,000 mg by 24-hour urine collection * INR ≤ 1.5 OR in-range INR between 2 and 3 if patient is on a stable dose of therapeutic warfarin * PTT ≤ 1.5 times ULN * Fasting cholesterol \< 350 mg/dL * Fasting triglycerides \< 400 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Seizures allowed provided they are controlled with standard medical therapy * No active infection requiring antibiotics, except uncomplicated urinary tract infection * No active bleeding or pathologic conditions that carry high risk of bleeding, (e.g., known bleeding disorder, coagulopathy, or tumor involving major vessels) * No serious, non-healing wound, ulcer, or bone fracture, including abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 3 months * No prior underlying lesions that caused the fistula or perforation that have not been corrected * No prior interstitial pneumonitis * No clinically significant cardiovascular disease, including any of the following: * Uncontrolled hypertension, defined as systolic blood pressure (BP) \> 150 mm Hg or diastolic BP \> 90 mm Hg * Myocardial infarction or unstable angina within the past 6 months * New York Heart Association class II-IV congestive heart failure * Serious cardiac arrhythmia requiring medication * Peripheral vascular disease ≥ grade 2 * No cerebrovascular accident, transient ischemic attack, or subarachnoid hemorrhage within the past 6 months * No uncontrolled diabetes * Hemoglobin A1C \< 10 * No other invasive malignancies within the past 5 years, except nonmelanoma skin cancer and other specific malignancies (e.g., localized breast, head and neck, or skin cancer that completed treatment \> 3 years prior to study and remain disease-free) * No significant traumatic injury within the past 28 days * No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies * Concurrent prophylactic or therapeutic anticoagulation\* (e.g., warfarin) allowed * Recovered from recent surgery, radiotherapy, or chemotherapy * No prior bevacizumab or other VEGF pathway-targeted therapy * No prior temsirolimus, everolimus, deforolimus, sirolimus, or any other mTor/PI3K pathway-targeted therapy * No prior non-cytotoxic chemotherapy for management of this disease, except hormonal therapy * At least 1 week since prior hormonal therapy directed at the malignant tumor * No prior therapy that contraindicates this protocol therapy * No prior radiotherapy to any portion of the abdominal cavity or pelvis within the past 5 years, except treatment of endometrial cancer * Prior radiotherapy for localized cancer of the breast, head and neck, or skin is allowed, provided it was completed \> 3 years prior to study entry and patient remains free of recurrent or metastatic disease * No prior chemotherapy for any abdominal or pelvic tumor within the past 5 years, except treatment of endometrial cancer * Prior adjuvant chemotherapy for localized breast cancer allowed, provided it was completed \> 3 years prior to study entry and the patient remains free of recurrent or metastatic disease * Prior treatment with an anthracycline (i.e., doxorubicin and/or liposomal doxorubicin) allowed provided ejection fraction \< 50% * More than 28 days since prior major surgery or open biopsy * More than 7 days since minor surgical procedures, fine needle aspirates, or core biopsies * At least 3 weeks since prior therapy directed at the malignant tumor, including immunologic agents * No concurrent major surgery * No concurrent prophylactic filgrastim (G-CSF) or thrombopoietic agents * No concurrent amifostine or other protective reagents